^
Association details:
| Biomarker: | DCTN1-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Alecensa (alectinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion
Published date:
12/28/2021
Excerpt:
NGS analysis of ctDNA revealed a rare ALK oncogenic fusion involving DCTN1 exon 26 and ALK exon 20 (level, plasma 0.23%), and no detectable T790M mutation….The patient was therefore treated with alectinib, and her symptoms significantly improved after 1 month with almost no noticeable side effects....The patient was evaluated with a PR, nearly complete response (CR), as revealed by chest CT, chest x-ray, and brain MRI 6 months later (Figure 1a, 2021 January).
DOI:
https://doi.org/10.1111/1759-7714.14291
